> top > docs > PubMed:32336586 > annotations

PubMed:32336586 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 0-15 CHEBI:52217 denotes Pharmacotherapy
T2 0-15 CHEBI:52217 denotes Pharmacotherapy
T3 19-27 SP_7 denotes COVID-19
T4 91-99 SP_7 denotes COVID-19
T5 547-555 SP_7 denotes COVID-19
T6 721-729 SP_7 denotes COVID-19
T7 767-804 CHEBI:35475 denotes non-steroidal anti-inflammatory drugs
T8 767-804 CHEBI:35475 denotes non-steroidal anti-inflammatory drugs
T9 806-812 CHEBI:35472 denotes NSAIDs
T10 806-812 CHEBI:35472 denotes NSAIDs
T11 851-861 CHEBI:35222 denotes inhibitors
T12 851-861 CHEBI:35222 denotes inhibitors
T13 973-981 SP_7 denotes COVID 19
T14 985-995 SP_7 denotes SARS-CoV-2
T15 1167-1172 CHEBI:23888 denotes drugs
T16 1167-1172 CHEBI:23888 denotes drugs
T17 1216-1226 SP_7 denotes SARS-CoV-2
T18 1257-1267 DG_28 denotes remdesivir
T19 1269-1280 NCBITaxon:31032 denotes favipiravir
T20 1269-1280 DG_17 denotes favipiravir
T21 1301-1312 CHEBI:3638 denotes chloroquine
T22 1301-1312 CHEBI:3638 denotes chloroquine
T23 1301-1312 DG_10 denotes chloroquine
T24 1314-1332 CHEBI:5801 denotes hydroxychloroquine
T25 1314-1332 CHEBI:5801 denotes hydroxychloroquine
T26 1314-1332 DG_20 denotes hydroxychloroquine
T27 1427-1445 CHEBI:5801 denotes hydroxychloroquine
T28 1427-1445 DG_20 denotes hydroxychloroquine
T29 1427-1445 CHEBI:5801 denotes hydroxychloroquine
T30 1446-1458 CHEBI:2955 denotes azithromycin
T31 1446-1458 DG_6 denotes azithromycin
T32 1446-1458 CHEBI:2955 denotes azithromycin
T33 1462-1473 CHEBI:3638 denotes chloroquine
T34 1462-1473 DG_10 denotes chloroquine
T35 1462-1473 CHEBI:3638 denotes chloroquine
T36 1478-1496 CHEBI:5801 denotes hydroxychloroquine
T37 1478-1496 DG_20 denotes hydroxychloroquine
T38 1478-1496 CHEBI:5801 denotes hydroxychloroquine
T39 1610-1620 DG_28 denotes Remdesivir
T40 1638-1644 UBERON:0001969 denotes plasma
T41 1689-1700 UBERON:0001004 denotes respiratory
T42 1761-1774 PR:000001393 denotes Interleukin-6
T43 1776-1780 PR:000001393 denotes IL-6
T44 1842-1858 GO:0019221 denotes cytokine release
T45 1875-1890 CHEBI:50858 denotes Corticosteroids
T46 1875-1890 CHEBI:50858 denotes Corticosteroids
T47 1968-1979 UBERON:0001004 denotes respiratory
T48 2058-2068 CHEBI:35222 denotes inhibitors
T49 2058-2068 CHEBI:35222 denotes inhibitors
T50 2122-2131 CHEBI:5855 denotes ibuprofen
T51 2122-2131 CHEBI:5855 denotes ibuprofen
T52 2285-2290 CHEBI:23888 denotes drugs
T53 2285-2290 CHEBI:23888 denotes drugs
T54 2324-2330 CHEBI:23888 denotes agents
T55 2324-2330 CHEBI:23888 denotes agents
T56 2482-2490 SP_7 denotes COVID-19

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 1689-1708 Phenotype denotes respiratory failure http://purl.obolibrary.org/obo/HP_0002878
T2 1842-1867 Phenotype denotes cytokine release syndrome http://purl.obolibrary.org/obo/HP_0033041
T3 1955-1960 Phenotype denotes shock http://purl.obolibrary.org/obo/HP_0031273
T4 1968-1988 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T5 2148-2153 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-72 Sentence denotes Pharmacotherapy in COVID-19; A narrative review for emergency providers.
T2 73-86 Sentence denotes INTRODUCTION:
T3 87-207 Sentence denotes The COVID-19 pandemic has been particularly challenging due to a lack of established therapies and treatment guidelines.
T4 208-335 Sentence denotes With the rapid transmission of disease, even the off-label use of available therapies has been impeded by limited availability.
T5 336-433 Sentence denotes Several antivirals, antimalarials, and biologics are being considered for treatment at this time.
T6 434-610 Sentence denotes The purpose of this literature review is to synthesize the available information regarding treatment options for COVID-19 and serve as a resource for health care professionals.
T7 611-622 Sentence denotes OBJECTIVES:
T8 623-904 Sentence denotes This narrative review was conducted to summarize the effectiveness of current therapy options for COVID-19 and address the controversial use of non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs).
T9 905-1119 Sentence denotes PubMed and SCOPUS were queried using a combination of the keywords "COVID 19," "SARS-CoV-2," and "treatment." All types of studies were evaluated including systematic reviews, case-studies, and clinical guidelines.
T10 1120-1131 Sentence denotes DISCUSSION:
T11 1132-1370 Sentence denotes There are currently no therapeutic drugs available that are directly active against SARS-CoV-2; however, several antivirals (remdesivir, favipiravir) and antimalarials (chloroquine, hydroxychloroquine) have emerged as potential therapies.
T12 1371-1609 Sentence denotes Current guidelines recommend combination treatment with hydroxychloroquine/azithromycin or chloroquine, if hydroxychloroquine is unavailable, in patients with moderate disease, although these recommendations are based on limited evidence.
T13 1610-1760 Sentence denotes Remdesivir and convalescent plasma may be considered in critical patients with respiratory failure; however, access to these therapies may be limited.
T14 1761-1874 Sentence denotes Interleukin-6 (IL-6) antagonists may be used in patients who develop evidence of cytokine release syndrome (CRS).
T15 1875-2053 Sentence denotes Corticosteroids should be avoided unless there is evidence of refractory septic shock, acute respiratory distress syndrome (ARDS), or another compelling indication for their use.
T16 2054-2154 Sentence denotes ACE inhibitors and ARBs should not be discontinued at this time and ibuprofen may be used for fever.
T17 2155-2166 Sentence denotes CONCLUSION:
T18 2167-2353 Sentence denotes There are several ongoing clinical trials that are testing the efficacy of single and combination treatments with the drugs mentioned in this review and new agents are under development.
T19 2354-2491 Sentence denotes Until the results of these trials become available, we must use the best available evidence for the prevention and treatment of COVID-19.
T20 2492-2605 Sentence denotes Additionally, we can learn from the experiences of healthcare providers around the world to combat this pandemic.
T1 0-72 Sentence denotes Pharmacotherapy in COVID-19; A narrative review for emergency providers.
T2 73-86 Sentence denotes INTRODUCTION:
T3 87-207 Sentence denotes The COVID-19 pandemic has been particularly challenging due to a lack of established therapies and treatment guidelines.
T4 208-335 Sentence denotes With the rapid transmission of disease, even the off-label use of available therapies has been impeded by limited availability.
T5 336-433 Sentence denotes Several antivirals, antimalarials, and biologics are being considered for treatment at this time.
T6 434-610 Sentence denotes The purpose of this literature review is to synthesize the available information regarding treatment options for COVID-19 and serve as a resource for health care professionals.
T7 611-622 Sentence denotes OBJECTIVES:
T8 623-904 Sentence denotes This narrative review was conducted to summarize the effectiveness of current therapy options for COVID-19 and address the controversial use of non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs).
T9 905-1119 Sentence denotes PubMed and SCOPUS were queried using a combination of the keywords "COVID 19," "SARS-CoV-2," and "treatment." All types of studies were evaluated including systematic reviews, case-studies, and clinical guidelines.
T10 1120-1131 Sentence denotes DISCUSSION:
T11 1132-1370 Sentence denotes There are currently no therapeutic drugs available that are directly active against SARS-CoV-2; however, several antivirals (remdesivir, favipiravir) and antimalarials (chloroquine, hydroxychloroquine) have emerged as potential therapies.
T12 1371-1609 Sentence denotes Current guidelines recommend combination treatment with hydroxychloroquine/azithromycin or chloroquine, if hydroxychloroquine is unavailable, in patients with moderate disease, although these recommendations are based on limited evidence.
T13 1610-1760 Sentence denotes Remdesivir and convalescent plasma may be considered in critical patients with respiratory failure; however, access to these therapies may be limited.
T14 1761-1874 Sentence denotes Interleukin-6 (IL-6) antagonists may be used in patients who develop evidence of cytokine release syndrome (CRS).
T15 1875-2053 Sentence denotes Corticosteroids should be avoided unless there is evidence of refractory septic shock, acute respiratory distress syndrome (ARDS), or another compelling indication for their use.
T16 2054-2154 Sentence denotes ACE inhibitors and ARBs should not be discontinued at this time and ibuprofen may be used for fever.
T17 2155-2166 Sentence denotes CONCLUSION:
T18 2167-2353 Sentence denotes There are several ongoing clinical trials that are testing the efficacy of single and combination treatments with the drugs mentioned in this review and new agents are under development.
T19 2354-2491 Sentence denotes Until the results of these trials become available, we must use the best available evidence for the prevention and treatment of COVID-19.
T20 2492-2605 Sentence denotes Additionally, we can learn from the experiences of healthcare providers around the world to combat this pandemic.